On December 23, 2023 3SBio Inc. and Numab Therapeutics ("Numab") reported today on a collaboration agreement, pursuant to which Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian"), a subsidiary of the Company, will develop and commercialize a portfolio of novel multi-specific antibodies for cancer therapy based on Numab’s technology platform (Press release, 3SBio, DEC 12, 2019, View Source [SID1234637791]). Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules emerging from up to three multi-specific antibody programs based on Numab’s R&D platform and has the exclusive licenses to develop and commercialize each of the selected antibody molecules in Greater China territories, including Mainland China, Hong Kong, Macao and Taiwan, while Numab retains exclusive commercial rights in the rest of the world. Concurrently, Sunshine Guojian has invested CHF15M (approximately USD15.2M) in Numab’s series B financing. Dr. Zhenping Zhu, MD, PhD, President of Research and Development, Chief Scientific Officer of 3SBio, has joined the Numab’s board of directors. Further financial terms were not disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Numab’s proprietary MATCH technology has generated a robust pipeline of multi-specific antibody drug candidates with its lead program ND021, an anti-4-1BB x PD-L1 x HSA tri-specific antibody, entering clinical trials in 2020. The alliance with Sunshine Guojian is a continuation of our strategy to work with committed, world-class partners in Asia that are ideally positioned to develop and commercialize our multi-specific antibodies in this important region. Our partnering model has allowed us to establish a growing pipeline of innovative drug candidates and retain key commercial rights in Europe and the US," commented Dr. David Urech, Chief Executive Officer of Numab. "Sunshine Guojian’s investment in our Series B will support Numab in the further expansion and advancement of our portfolio of multi-specific antibodies."
"The investment and collaboration with Numab are consistent with our goal to explore promising therapeutic strategies that address the significant unmet medical needs of cancer patients in China," said Dr. Jing Lou, Chairman and Chief Executive Officer of 3SBio, "Accessing Numab’s cuttingedge multi-specific antibody technology platform and its product portfolio in immune-oncology complements our existing R&D establishment and strategy. 3SBio regards innovation in research and development as a main pillar of the enterprise and we are looking forward to collaborating with the Numab team."
Multi-specific antibodies have the potential to unlock entirely novel modes-of-action aiming at superior benefit-to-risk profiles relative to conventional cancer immune therapies. Numab’s proprietary MATCH technology platform represents one of the most versatile and flexible sources for multi-specific antibodies. MATCH molecules can incorporate up to six binding specificities in true plug-and-play fashion. The individual antibody Fv building blocks are designed for maximum stability and developability.